FDA Lifts Hold on Mersana’s Antibody-Drug Conjugate Following Patient Death

FDA Lifts Hold on Mersana’s Antibody-Drug Conjugate Following Patient Death

Submitted by admin on November 2, 2023 - 11:42am
Source: 
BioSpace
News Tags: 
Mersana Therapeutics
XMT-2056
clinical trials
FDA
antibody drug conjugate
Headline: 
FDA Lifts Hold on Mersana’s Antibody-Drug Conjugate Following Patient Death
snippet: 

The FDA has lifted its full clinical hold on Mersana Therapeutics’ Phase I study of XMT-2056, its investigational STING-directed antibody-drug conjugate, the company announced Tuesday.

Do Not Allow Advertisers to Use My Personal information